RPS Diagnostics, Inc., a Sarasota, FL-based developer, manufacturer, and marketer of rapid point-of-care (POC) diagnostic tests, closed a $28m of non-dilutive debt financing with OrbiMed.
This financing will allow the company to extend the reach of its commercial infrastructure and support the advancement of its product development pipeline.
Founded in 2004 and led by Robert Sambursky, chief executive officer and president, RPS Diagnostics develops, manufactures, and markets rapid point-of-care (POC) diagnostic tests. The company’s patented technology platform facilitates the development of a spectrum of cost-effective tests to support the rapid diagnosis of patients with infectious diseases and inflammatory conditions. As a result of U.S. government contracts, this platform is also being developed to help detect the body’s immune response to viral and bacterial infections as well as chemical nerve agent blood toxins.
Currently available RPS tests include AdenoPlus® to aid in the diagnosis of Adenoviral conjunctivitis (pink eye) and InflammaDry® to aid in the diagnosis of dry eye disease.